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Background: Conceptual reviews and observational studies describe a link between physical inactivity and behavioural
disturbances in people with dementia. Consequently, treatment of these symptoms requires physical activation and
pharmacological or physical immobilization should be avoided. The few trials that have been conducted in inpatient
dementia care to investigate the effects of exercise on behavioural and psychological symptoms revealed inconsistent
results. Due to a lack of evidence, there is a paucity of recommendations for physical activation in this stage of care.
Therefore, this trial seeks to investigate the effects of a day-structuring exercise programme on behavioural and
psychological symptoms as well as on circadian rhythms of patients with dementia, hospitalized because of their
behavioural and psychological disturbances.
Methods/Design: A single-centre randomised controlled trial will be conducted in three special dementia care units
of an old age psychiatry hospital. Enrolled patients will receive either a 2-week exercise programme, or a 2-week social
stimulation programme in addition to usual care. Due to the provision of four day-structuring exercise-sessions in the
course of an intervention day, the exercise programme for the study group is called exercise-carrousel. Baseline and
post-intervention assessment for the primary outcome variable - the overall effects on behavioural and psychological
symptoms - will be measured by the Alzheimer's disease Cooperative Study-Clinical Global Impression of Change. The
following objectives are set up as secondary outcomes: dimensions of the behavioural and psychological symptoms of
dementia (BPSD) and caregiver burden, routine and on-demand psychotropic medication, patients’ motor behaviour,
diurnal cortisol-levels from saliva probes and brain-derived neurotrophic factor-levels from blood serum.
Discussion: In order to be regarded as an important treatment option for behavioural and psychological symptoms,
physical activation in inpatient hospital dementia care requires more evidence and appropriate recommendations.
Respecting hospital routines and the intra-daily variability of the patients’ motivation and behavioural disturbances in
the provision of exercise sessions could lead to higher exercise adherence and better effects on patients’ behavioural
and psychological symptoms than former trials have presented. The concealment of allocation throughout the trial and
the rating of individual exercise exertion present the key challenges and main limitations of this trial.
Trial registration: DRKS00006740 (German Clinical Trial Register, date of registration: 28 October 2014).
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The treatment of behavioural and psychological symp-
toms of dementia (BPSD) is a key challenge in inpatient
dementia care [1, 2]. During the course of the disease
nearly every patient suffers from an exacerbation of be-
havioural and psychological symptoms. Due to extreme
caregiver and environmental burden, such phases often
lead to admission into specialised Dementia Care Units
(DCU) in old age psychiatric departments.
The application of antipsychotic medication is a standard
treatment method for behavioural disturbances in inpatient
dementia care. Owing to potential side effects of neurolep-
tics [3], clinicians seek non-pharmacological approaches
for the treatment of BPSD [4]. A conceptual review [5] and
an observational, cross-sectional trial [6] describe a direct
link between physical inactivity and increased behavioural
disturbances. Considering these findings, more physical
activation in DCU is recommended, possibly leading to
a reduced use of sedative medication and physical con-
straints. This non-pharmacological approach shows the
positive effects of physical activation and may help to
reduce critical side-effects of psychopharmacotherapy.
Unlike the good evidence for exercise as a key-
factor in the prevention of dementia [7–9], research
focussing on the effects of exercise in dementia care
is in its ‘infancy’ [10]. While exercise trials focussing
on functional performance and activities of daily liv-
ing show promising results [11, 12], there is a paucity
of clinical trials investigating the effects of exercise
on BPSD. While trials in long-term nursing home
care reveal promising effects on some BPSD - especially
on mood, agitation and circadian disturbances - there are
only a few clinical studies in inpatient hospital dementia
care with consistent results [13]. The Cochrane Re-
view by Forbes et al. [11] includes only one trial in-
vestigating the effects of exercise on BPSD [14]. This
1-year nursing-home exercise trial, conducted with
an overall participation-rate of 30 %, showed no effects
on BPSD [14]. As the low level of participation and
consequently low level of physical activation could be a
determining factor explaining only minimal effects on
BPSD, future research should focus on approaches with
better exercise adherence and higher levels of physical
activation [6].
In addition to physical activation, the organisation of
non-pharmacological treatment in the course of a day
is a key component of inpatient dementia care [15].
Disease-related changes in circadian motor behaviour,
that is, wandering, agitation or sundowning, affect al-
most every patient in advanced stages of dementia [16].
In this context, sundowning is denoted as an increase
of BPSD in the late afternoon and early evening hours.
As a low level of daytime activity is linked to a higher
fragmentation of circadian rest-activity cycles [17],structured exercise programmes may help to synchron-
ise and reduce circadian rhythm disturbances [16, 18].
Taking into account the assumed positive effects of
physical exercise on BPSD and the necessity of pro-
viding day structure through activities in dementia
care, our research group has conducted a pilot study.
The aim of this pilot study was to investigate the
feasibility of the planned day-structuring physical
activation programme in a hospital setting. Eighteen
patients suffering from acute exacerbation of behav-
ioural symptoms in dementia were included. These
patients received a 2-week complex day-structuring exer-
cise programme in addition to their usual treatment - the
same intervention as planned for the randomised con-
trolled trial (RCT). Two thirds of these patients accom-
plished more than 180 minutes of exercise per week. In
this pilot-study we found reductions in some BPSD; fur-
thermore we found stabilisation of day-structure and a
decrease in caregiver burden. Based on these preliminary
findings, our planned RCT trial aims to investigate the
effects of a day-structuring exercise programme in in-
patient hospital dementia care.
Objectives
The primary objective of this trial is to investigate the ef-
fects of a day-structuring exercise programme on BPSD in
inpatient hospital dementia care. The promising results of
our pilot-study regarding the feasibility and effects of the
exercise-carrousel on BPSD in hospital old age psychiatry
care, led to the following study-hypothesis:
The intervention group, carrying out a 2-day-structuring
exercise intervention in addition to treatment as
usual (TAU), is hypothesized to show reduced BPSD
at follow-up. In contrast, the control group, receiving
social stimulation in addition to TAU, is not expected
to show such changes.
In addition to investigating the putative effects of the
day-structuring exercise on BPSD, the following secondary-
endpoint parameters are investigated: caregiver burden,
total dose and frequency of application of antipsychotic and
sedative medication, circadian rhythms of motor behaviour,
saliva cortisol-levels and brain-derived neurotrophic factor.
Methods/Design
Design
An RCT with pre- and post-intervention-assessment
(Fig. 1) will be conducted in the department of old age
psychiatry at the LVR-Hospital Cologne, an academic
teaching hospital of the University of Cologne. All asses-
sors of eligibility criteria and outcome measurements
will be blinded to group allocation. Ethical approval was
obtained by the Ethics Commission of the German Sport
Fig. 1 Trial flow chart
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North-Rhine Medical Chamber (reference number:
2014216). This trial is registered in the German National
Register of Clinical Trials (DRKS00006740).
Sample
Patients from three special DCU of the LVR-Hospital
Cologne will be screened by two senior psychiatrists,
who are not part of the study team, based on the follow-
ing inclusion criteria: diagnosis of dementia according to
ICD-10-criteria [19] and a minimum length of stay of
one week before enrolment into the study, in order to
help patients get familiarised to the new ward setting
and to exclude delirium. Clinical exclusion of delirium is
furthermore based on the validated German version of
the Confusion-Assessment-Method, which is performed
in all eligible patients [20, 21]. Patients must be able to
perform the Timed Up and Go Test (TuG) [22]. Written
consent of the patients’ legal guardian as well as from
the patient is required. Patients will be excluded accord-
ing to the following criteria: symptomatic, non-vascular
or non-neurodegenerative dementia, no legal guardian,
cardiac diseases denying exercise participation; and ag-
gressive behaviour that prevents participation in groups.
Sample size
The calculation of the sample size was performed via
G*Power 3.1 [23], taking into account following parame-
ters: a medium effect size (d = 0.5) for the primary objec-
tives, the overall effects on BPSD measured by the
Alzheimer’s Disease Cooperative Study-Clinical Global
Impression of Change (ADCS-CGIC) [24, 25], from our
pilot-study; a 1:1 allocation rate; two measurements;non-parametric analysis due to ordinal characteristics of
the instruments assessing the primary objective; and an
α-error of 0.05 and a power of 0.80 (1-ß-error) according
to Cohen [26]. Based on this calculation, each group
shall include 53 patients. The enrolment of 130 patients
is planned, as a drop-out rate of 25 % is expected based
on the experience from the pilot study.
Allocation and concealment of allocation
After enrolment and pre-assessment (T0, Fig. 1), group
allocation to the study or control group will be realised
via minimisation. An external statistician, who is not
part of the study team, will run the group allocation via
an online minimisation-tool ‘Qminim’ [27]. Minimisa-
tion is a well-approved form of randomisation that mini-
mises group differences in pre-defined characteristics
while continuing trial enrolment. In order to achieve the
best possible balance between the two study arms, group
allocation will be performed according to the following
factors: sex (double weighted), age, Mini-Mental Status-
Examination (MMSE) [28] and Bayer instrumental Ac-
tivities of Daily Living (B-ADL) [29]. Due to external
enrolment in the trial, central randomisation by a person
not involved in the study, and the blinding of all investiga-
tors during the whole trial, allocation concealment will be
realised in the course of the trial.
Sample characteristics
Baseline characteristics will be recorded within the geri-
atric assessment, carried out by nursing and medical
staff members of the LVR-Hospital Cologne, who are
not part of the study team. This basic assessment in-
cludes sex, age, body-mass-index, type of dementia, the
MMSE [28], the clock draw test [30], assessment of the
cognitive reserve capacity according to Stern [31], TuG
[22], the 10-meter gait speed [32] and B-ADL [29].
Outcome measures
All outcome measurements will be conducted by experi-
enced assessors from nursing and medical staff, blinded
to group allocation. Primary and secondary outcome
variables are presented in Table 1.
As the overall effect of our intervention on BPSD as
rated by the ADCS-CGIC [24, 25] is the primary out-
come, that is the measure on which we will focus.
Secondary outcome measures include dimensions of
BPSD rated by the Neuropsychiatric Inventory (NPI) [33]
and the Cohen-Mansfield-Agitation-Inventory (CMAI)
[34]. All psychopathometric assessments will be accom-
plished by blinded investigators, who are responsible for
interviewing both the caregiver as well as the medical and
nursing staff. Further secondary outcome variables include
the assessment of caregiver burden via the NPI-caregiver-
subscale [33] and the effects on the application of two
Table 1 Objectives and instrumental set-up of the trial
Variable Instrument
Primary objective Behavioural and psychological symptoms (BPSD) Alzheimer’s Disease Cooperative Study-Clinical Global Impression of
Change [33]
Secondary objective Dimensions of BPSD Neuropsychiatric Inventory (NPI) [35]
Cohen-Mansfield-Agitation-Inventory [36]
Caregiver burden NPI-caregiver-subscale [35]
Application of antipsychotics Chlorpromazine-equivalents [34]
Application of benzodiazepine Diazepam-equivalents [36]
Motor behaviour Body fixed motion sensor
Saliva cortisol levels Demeditec™ saliva kits [42]
Neurotrophic factor levels Brain-derived neurotrophic factor from blood-serum probes [44]
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benzodiazepines. The individual dosage per day of routine
and pro-re-nata medication will be converted for antipsy-
chotics to Chlorpromazine equivalents [35] and for benzo-
diazepines to Diazepam-equivalents [36, 37]. The patients’
motor behaviour will be assessed by an inertial body-fixed
sensor system. Body postures will be detected in four
periods of 72 consecutive hours (see Fig. 2), based upon
accelerometer, gyroscope, and magnetoscope data. As
recommended by Trost et al. [38], the sensor system
will be placed at the nearest possible position to the
body centre of mass, the lower back. In accordance to
Hatfield et al. [39], diurnal saliva cortisol-levels will be
assessed every four hours from 08:00 a.m. to 12:00 p.m.
on two consecutive days at T0 and T1 with Demeditec™
saliva kits (Demeditec Diagnostics GmbH, Kiel, Germany)
[40]. Analysis of saliva cortisol-levels will be carried out
via an enzyme-linked immunosorbent assay (ELISA). In
order to analyse the effects on brain-derived neurotrophic
factor (BDNF), blood-samples will be taken on the first
intervention day at 08:30 a.m., at 05:00 p.m. and for T1 at
08:30 a.m. These samples will be centrifuged, blood serum
will be stored in a fridge by -40 °C and the ELISA analysis
will be realised via R & D Systems™ (R&D Systems Inc.,
Minneapolis, USA) [41–43]. Adverse events are recorded
and a potential relation to the intervention will be evalu-
ated by a senior old age psychiatrist, who is not part of the
study team.Fig. 2 Schedule of body-fixed sensor assessment of patient motor behavio
the intervention (Int 0); at the end of the intervention (Int 1) and after theIntervention
TAU includes exercise therapy for 45 minutes twice
weekly. Patients within the study group will receive a 2-
week exercise programme. On 3 non-consecutive days
of the week, the patients allocated to the study-group
will be offered four exercise sessions a day (see Table 2).
In order to ease the patients’ participation, the exercise
instructor will see the patient on his ward and ask him
to take part in an exercise session. If the patient refuses
or is hindered for other reasons, the exercise instructor
will, however, see the patient at the next scheduled exer-
cise session (Table 2) and offer him further participation.
After positive feedback, a single session will be held for
a net time of 20 minutes. After one exercise session,
there will be a rest period of one hour. This specific time
schedule will be carried out four times on each interven-
tion day. Due to the provision of recurrent rest-activity
periods throughout a day, this activation programme is
called exercise-carrousel. The patients will be allocated
to three different exercise groups with a maximum of
three patients per instructor. Two exercise sessions
include endurance exercise on seated-ergometers for
the upper and lower limb. Furthermore, two exercise
sessions focusing on strengthening exercises with
wrist- and ankle-worn weights will be carried out. The
net exercise time of 20 minutes includes two minutes
of warm-up at the beginning and two minutes of cool
down at the end. An endurance-exercise-period ofur. Legend: Four 72-h episodes at baseline (T0); at the beginning of
intervention (T1)
Table 2 Exercise carrousel schedule for one intervention day
Time/Group a.m. p.m.
09:00 09:30 10:00 10:30 11:00 11:30 00:00 to 02:00 02:00 02:30 03:.00 03:30 04:00 04:30
Group 1 I II Lunch break III IV
Group 2 I II III IV
Group 3 I II III IV
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will be carried out.
Strengthening sessions include six standardised strength-
ening exercises for the lower limb with two to five kilo-
gramme ankle-worn weights on both legs (sit-stand,
knee-extension in sitting position, standing heel-raise,
knee-curl in standing position, hip-abduction and hip-
extension in standing position); for the upper limb with
1- to 2-kg wrist-worn weights on both arms (biceps-curl,
extended shoulder-lift in sitting position, rowing in 90°
shoulder-abduction, shoulder-lift and shoulder-abduction
in standing, dips on arm rest while sit-stand).
These strengthening exercises will run in two sets of
twelve repetitions each. The exercise load will be increased
progressively after each intervention day in increments of
1 kg for the lower limb and a 0.5 kg for the upper limb.
An increase in exercise load requires optimal exercise
execution regarding both range of motion and scheduled
repetitions. Endurance exercise sessions are conducted
with a scheduled intensity of one watt per kilogramme of
body weight in upper and lower limb exercises. If the exer-
cise sessions a) are adequately executed and b) no serious
complications occurred, the exercise load will be aug-
mented up to 1.5 watt per kilogramme body weight. In
accordance to Edwards et al. [44] exercise adherence
will be recorded for each exercise session, and not only
physical presence will be considered but also the degree
to which the scheduled exercise session was completed.
For participation to be rated as complete, more than
50 % of the scheduled exercise load regarding time, inten-
sity and adequate repetitions is required.
The average participation rate of subjects in our pilot
study was 120 min/week. For our RCT, we expect the
same average participation duration for the intervention
group. In order to receive a comparable level of social
stimulation to the study group, the patients in our con-
trol group will be offered two 1-hour sessions of social
interaction (table games) per week.
Analysis
The patients’ baseline characteristics in both groups will
be compared via Chi-square test for categorical data,
Wilcoxon rank test for non-parametric or non-normally
distributed characteristics and T-test for continuous and
normally distributed characteristics. Pre-post-outcome
analysis within and between the groups will be realisedper intention-to-treat analysis for the primary outcome
variable via Friedman analysis of variance (ordinal charac-
teristics) and analysis of variance for interval characteris-
tics. The analysis of circadian rhythms in motor behaviour
will be conducted according to Witting et al. [45] by calcu-
lating inter-daily stability, intra-daily variability and relative
amplitude. Advanced time series analysis of the patients’
daily activity patterns will be developed in accordance with
recent developments by Kirste et al. [46]. Analysis of the
patients’ characteristics and outcome criteria will be rea-
lised using SPSS (version 22) and Matlab (version R2014b).
Discussion
The treatment of BPSD is challenging as patients with
dementia are prone to suffer from severe side effects of
pharmacotherapy [47]. Furthermore, psychopharma-
cotherapy often has no significant effects on BPSD or
may even worsen behavioural symptoms in the patients
[48]. Therefore, non-pharmacological approaches for
the treatment of BPSD are essential. Establishing non-
pharmacological treatment and especially physical acti-
vation therefore represent a fruitful and promising
approach [5]. Hence, we plan to implement a hospital-
based day-structuring exercise programme for demented
patients suffering from exacerbated behavioural symptoms.
To our knowledge, this is the first randomised con-
trolled trial in inpatient hospital dementia care investi-
gating the effects of multiple exercise sessions in the
course of a day. Whereas former intervention trials and
routine inpatient dementia care provide exercise sessions
in a rigid time schedule for approximately one hour per
session [14], this trial offers four flexible short-time
exercise sessions throughout a day. In a hospital set-
ting, ward routines and intra-daily variations of the
patients’ mood or behaviour are most reasons for non-
participation in exercise sessions. If a patient has no
motivation to take part in an exercise session, or is
hindered due to nursing or medical routines, there is
in most cases no further chance to take part in guided
physical activation throughout the same day. In order
to circumvent these problems, the exercise-carrousel
schedule offers multiple low-threshold exercise sessions
during a day. From our clinical experience, this exercise
programme should increase the patients’ willingness for
participation. Therefore, we expect a better exercise-
adherence compared to routine care and former trials
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accordance with Christofoletti et al. [6], this programme
represents an innovative strategy to increase exercise-
adherence in dementia patients, thereby possibly leading
to decreased BPSD.
Additionally, we are also interested in the influences
on circadian rhythm disturbances. Disrupted circadian
motor behaviour is often seen in demented patients; that
is, fragmentation of rest-activity cycles or wandering-
phenomenon. Actually, there are recommendations to
perform exercise sessions in the morning hours [49]. As
behavioural disturbances more often occur in the after-
noon and evening hours, Rimmer and Smith [49] were
more concerned with behavioural disturbances that may
intervene with exercise sessions at that time. In most
hospital and nursing home settings, physical and occu-
pational therapy is therefore centred in the morning
hours. Consequently, in daily routines for dementia
patients there is often a lack of guided activities in the
afternoon and evening hours. National guidelines and
international expert panels demand the provision of day
structure as non-pharmacological treatment of circadian
rhythm disruptions [15, 50, 51]. To our knowledge, no
trial focussing on the provision of day structure through
physical activation in dementia care has been conducted
so far [15, 51].
We plan a trial that provides structured rest- and
activity-sequences in the course of a day and investigates
the synchronising effects on circadian rhythm distur-
bances. Intervention days are planned on three non-
consecutive days a week in addition to usual care with
daily co-therapies, nursing and medical applications. To
our knowledge there is no evidence, and neither are
there recommendations, for daily structured activities as
treatment of circadian rhythm disturbances. Within the
thrice weekly exercise schedule, we expect a day of rest
to be necessary for the patients and for the evaluation of
exercise effects on circadian disruptions on intervention
and non-intervention-days. Based on the experiences
from our pilot project, a day of rest between the interven-
tion days seems to be useful for these older population
patients.
In order to appropriately assess behavioural symptoms,
circadian rhythm disruptions and the effects of the
day-structuring exercise schedule, we suggest an innovative
combination of body-fixed motion sensors, well-established
instruments for the rating of BPSD (NPI, CMAI) and
physiological parameters (saliva-cortisol, BDNF). The up-
coming complementary use of hybrid motion sensors is an
especially important methodological advancement evaluat-
ing the association between disrupted motor activity and
behavioural symptoms in dementia [46]. Wrist-worn accel-
erometers, logging and analysing the periodicity of limb
movements on the basis of activity counts, are usually usedto investigate movement behaviour and circadian rhythm
disruptions [52]. Sensors logging the periodicity of body
postures, may be superior to activity counts in analysing
these symptoms. The results of our planned trial may help
to implement and improve the clinical use of body-fixed
sensors in assessing circadian and behavioural symptoms in
patients suffering from dementia [46, 53].
Considering the methodological issues, a major chal-
lenge in conducting clinical trials is to prevent selection
bias and achieve allocation concealment for all investiga-
tors throughout the whole trial. Therefore, all investiga-
tors involved in the assessment of patients (BPSD, motor
behaviour, cortisol, BDNF) and the staff of the ward are
blinded to group allocation. Trial design as well as the
definition and recording of intervention adherence are
important features when conducting exercise trials in
patients with dementia. In accordance to Edwards et al.
[44], we will rate exercise adherence regarding time, in-
tensity and degree of exercise performance. We do not
plan to use standardised self-reported rating scales to as-
sess exercise exertion (for example, via Borg score [54]),
as these scores are not reliable in patients with advanced
dementia [55]. Apart from the application of body-fixed
motion sensors, which provide reliable and objective in-
formation about motor behaviour during participation in
exercise sessions, there is no further monitoring of exer-
cise exertion planned for this trial. On the one hand, the
monitoring of heart rate and blood pressure during exer-
cise participation has not been feasible during the pilot
project. These patients were often distracted and some-
times refused to wear the monitoring devices. On the
other hand, we experienced small motor sensors fixed
on the lower back to be out of the patients’ focus and
therefore to be well accepted. The lack of instrumental
monitoring of exercise exertion represents a limitation
of this trial. Because this pragmatic method favours the
provision of best possible low-threshold exercise partici-
pation, with the lowest possible obstruction before and
during an exercise session, this approach has possible
methodological limitations, but it is also a simple, trans-
ferable approach for routine care. Furthermore, the 2-
week intervention phase only allows investigation into
the short-term effects of the exercise programme. Taking
into account the regular stay length of 4 to 5 weeks in
inpatient old age psychiatric hospital care, the design of
this trial schedules a 2-week intervention phase, due to
1 week after admission for familiarisation with the set-
ting and delirium exclusion, and 3 days for pre- and
post-assessment, respectively. Apart from the usually
recommended long-term exercise schedules, the investi-
gation of an intensive short-term exercise-carrousel
programme represents, from our point of view, an ap-
propriate and easily transferable approach at this stage
of care. Obviously, this intensive exercise intervention
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and may negatively interact with other hospital routines.
Physical activation is a key part of non-pharmacological
treatment, but despite the clinicians’ advice to apply
non-pharmacological methods for the treatment of
BPSD [4], there are no recommendations and guidelines
for inpatient hospital dementia care. The results of our
study may help to increase the evidence in the field of
exercise science and non-pharmacological treatment.
The exercise-carrousel approach can further advance
non-pharmacological treatment, leading to potential
worthwhile developments for patients, medical staff
and caregivers in dementia care.
Trial status
Recruitment began in April 2015
Abbreviations
ADCS-CGIC: Alzheimer’s Disease Cooperative Study-Clinical Global Impression
of Change; B-ADL: Bayer instrumental activities of daily living; BDNF: brain-derived
neurotrophic factor; BPSD: behavioural and psychological symptoms of
dementia; CMAI: Cohen-Mansfield agitation inventory; DCU: dementia care unit;
ELISA: enzyme-linked immunosorbent assay; MMSE: mini-mental status-
examination; NPI: neuropsychiatric inventory; RCT: randomised controlled trial;
TAU: treatment as usual; TUG: timed up and go-test.
Competing interests
Tim Fleiner, Wiebren Zijlstra, Hannah Dauth and Peter Haussermann declare
that they have no competing interests.
Authors’ contributions
All authors were involved in planning and writing the exercise carrousel
study protocol, all have read and approved the final manuscript.
Furthermore, TF is responsible for the implementation and performance of
the exercise intervention; WZ is responsible for the implementation and
analysis of motion sensors; HD is responsible for saliva and blood probes;
PH is responsible for adequate in- and exclusion of patients. All authors read
and approved the final manuscript.
Acknowledgements
We thank the board of directors of LVR-hospital cologne and the staff of the
old age psychiatry department for their willingness to support this trial.
Execution of the trial is funded by the authors’ institutional budgets.
Received: 24 January 2015 Accepted: 13 May 2015
References
1. Small GW. Treating dementia and agitation. JAMA. 2014;311:677–8.
2. Lyketsos CG, Carrillo MC, Ryan JM, Khachaturian AS, Trzepacz P, Amatniek J,
et al. Neuropsychiatric symptoms in Alzheimer’s disease. Alzheimers
Dement. 2011;7:532–9.
3. US Food and Drug Administration: Public Health Advisory: Deaths




4. Fairbairn A, Gould N, Kendall TD. Supporting people with dementia and
their carers in health and social care. Manchester: National Institute for
Health and Care Excellence; 2006. clinical guideline 42.
5. Scherder EJA, Bogen T, Eggermont LHP, Hamers JPH, Swaab DF. The more
physical inactivity, the more agitation in dementia. Int Psychogeriatr.
2010;22:1203–8.
6. Christofoletti G, Oliani MM, Bucken-Gobbi LT, Gobbi S, Beinotti F, Stella F.
Physical activity attenuates neuropsychiatric disturbances and caregiver
burden in patients with dementia. Clinics. 2011;66:613–8.7. Gauthier CJ, Lefort M, Mekary S, Desjardins-Crépeau L, Skimminge A, Iversen
P, et al. Hearts and minds: linking vascular rigidity and aerobic fitness with
cognitive aging. Neurobiol Aging. 2014;36:304–14.
8. Lange-Asschenfeldt C, Kojda G. Alzheimer’s disease, cerebrovascular
dysfunction and the benefits of exercise: from vessels to neurons. Exp
Gerontol. 2008;43:499–504.
9. Newson RS, Kemps EB. Cardiorespiratory fitness as a predictor of successful
cognitive ageing. J Clin Exp Neuropsychol. 2006;28:949–67.
10. Lautenschlager NT. Physical activity in Alzheimer’s disease: research in its
infancy or why we need more randomized controlled trials. Int
Psychogeriatr. 2014;26:7.
11. Forbes D, Thiessen EJ, Blake CM, Forbes SC, Forbes S. Exercise programs for
people with dementia. Update 2013. http://summaries.cochrane.org/
CD006489/exercise-programs-for-people-with-dementia; date accessed:
18.12.2013.
12. Burge E, Kuhne N, Berchtold A, Maupetit C, Gunten A. Impact of physical
activity on activity of daily living in moderate to severe dementia: a critical
review. Eur Rev Aging Phys Act. 2012;9:27–39.
13. Thuné-Boyle ICV, Iliffe S, Cerga-Pashoja A, Lowery D, Warner J. The effect of
exercise on behavioral and psychological symptoms of dementia: towards a
research agenda. Int Psychogeriatr. 2012;24:1046–57.
14. Rolland Y, Pillard F, Klapouszczak A, Reynish E, Thomas DR, Andrieu S,
et al. Exercise program for nursing home residents with Alzheimer’s
disease: a
1-year randomized, controlled trial. J Am Geriatr Soc. 2007;55:158–65.
15. Cohen-Mansfield J, Thein K, Dakheel-Ali M, Marx MS. Engaging nursing
home residents with dementia in activities: the effects of modeling,
presentation order, time of day, and setting characteristics. Aging Ment
Health. 2010;14:471–80.
16. Coogan AN, Schutová B, Husung S, Furczyk K, Baune BT, Kropp P, et al. the
circadian system in alzheimer’s disease: disturbances, mechanisms, and
opportunities. Biol Psychiatry. 2013;74:333–9.
17. Van Someren EJW, Hagebeuk EE, Lijzenga C, Scheltens P, Rooij SED, Jonker
C, et al. Circadian rest-activity rhythm disturbances in Alzheimer’s disease.
Biol Psychiatry. 1996;40:259–70.
18. Atkinson G, Edwards B, Reilly T, Waterhouse J. Exercise as a synchroniser of
human circadian rhythms: an update and discussion of the methodological
problems. Eur J Appl Physiol. 2007;99:331–41.
19. World Health Organisation. International Statistical Classification of Diseases
and Related Health Problems 10th Revision. Chapter V: Mental and
behavioural disorders (F00-F99). http://apps.who.int/classifications/icd10/
browse/2015/en#/V; date accessed: 10.01.2015.
20. Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying
confusion: the confusion assessment method. A new method for detection
of delirium. Ann Intern Med. 1990;113:941–8.
21. Hestermann U, Backenstrass M, Gekle I, Hack M, Mundt C, Oster P, et al.
Validation of a German version of the confusion assessment method for
delirium detection in a sample of acute geriatric patients with a high
prevalence of dementia. Psychopat. 2009;42:270–6.
22. Podsiadlo D, Richardson S. The timed “Up & Go”: a test of basic functional
mobility for frail elderly persons. J Am Geriatr Soc. 1991;39:142–8.
23. Faul F, Erdfelder E, Lang A, Buchner A. G*Power 3: a flexible statistical power
analysis program for the social, behavioral, and biomedical sciences. Behav
Res Methods. 2007;39:175–91.
24. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, et al.
Validity and reliability of the Alzheimer’s disease cooperative
study-clinical global impression of change. Alzheimer Dis Assoc Disord.
1997;2(11 Suppl):S22–32.
25. Drye LT, Ismail Z, Porsteinsson AP, Rosenberg PB, Weintraub D, Marano C,
et al. Citalopram for agitation in Alzheimer’s disease: design and methods.
Alzheimers Dement. 2012;8:121–30.
26. Cohen J. Statistical power analysis for the behavioral sciences. New York,
N.Y: Psychology Pres; 1988.
27. Saghaei M. Implementation of an open-source customizable minimization
program for allocation of patients to parallel groups in clinical trials.
J Biomed Sci Eng. 2011;4:734–9.
28. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical
method for grading the cognitive state of patients for the clinician.
J Psychiatr Res. 1975;12:189–98.
29. Hindmarch I, Lehfeld H, de Jongh P, Erzigkeit H. The Bayer Activities of Daily
Living Scale (B-ADL). Dement Geriatr Cogn Disord. 1998;9(Suppl) 2:20–6.
Fleiner et al. Trials  (2015) 16:228 Page 8 of 830. Sunderland T, Hill JL, Mellow AM, Lawlor BA, Gundersheimer J, Newhouse
PA, et al. Clock drawing in Alzheimer’s disease. A novel measure of
dementia severity. J Am Geriatr Soc. 1989;37:725–9.
31. Stern Y. What is cognitive reserve? Theory and research application of the
reserve concept. J Int Neuropsychol Soc. 2002;8:448–60.
32. Ries JD, Echternach LN, Gagon BM. Test-retest reliability and minimal
detectable change scores for the timed “up & go” test, the six-minute
walk test, and gait speed in people with Alzheimer disease. Phys Ther.
2009;89:569–79.
33. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J.
The Neuropsychiatric Inventory: comprehensive assessment of psychopathology
in dementia. Neurology. 1994;44:2308–14.
34. Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a
nursing home. J Gerontol. 1989;44:M77–84.
35. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho B. Antipsychotic dose
equivalents and dose-years: a standardized method for comparing exposure
to different drugs. Biol Psychiatry. 2010;67:255–62.
36. Holzbach R, Martens MS, Kalke J, Raschke P. Zusammenhang zwischen
Verschreibungsverhalten der Arzte und Medikamentenabhängigkeit ihrer
Patienten. Bundesgesundheitsblatt Gesundheitsforschung
Gesundheitsschutz. 2010;53:319–25.
37. Bezchlibnyk-Butler KZ, Jeffries JJ, Virani AS. Clinical handbook of
psychotropic drugs. 18th ed. Ashland, Ohio, London: Hogrefe & Huber;
Momenta [distributor]; 2009.
38. Trost SG, Mc Iver KL, Pate RR. Conducting accelerometer-based
activity assessments in field-based research. Med Sci Sports Exerc.
2005;37:S531.
39. Hatfield CF, Herbert J, van Someren EJW, Hodges JR, Hastings MH.
Disrupted daily activity/rest cycles in relation to daily cortisol rhythms of
home-dwelling patients with early Alzheimer’s dementia. Brain.
2004;127:1061–74.
40. Demeditec Diagnostics GmbH: Cortisol free in Saliva ELISA. http://dm.nimc.de/
de/produkte-details/productid/cortisol_free_in_saliva_elisa-1/; date accessed:
18.12.2014
41. Laske C, Stransky E, Leyhe T, Eschweiler GW, Wittorf A, Richartz E, et al.
Stage-dependent BDNF serum concentrations in Alzheimer’s disease. J
Neural Transm. 2006;113:1217–24.
42. Coelho FGM, Gobbi S, Andreatto CAA, Corazza DI, Pedroso RV, Santos-
Galduróz RF. Physical exercise modulates peripheral levels of brain-derived
neurotrophic factor (BDNF): A systematic review of experimental studies in
the elderly. Arch Gerontol Geriatr. 2013;56:10–5.
43. R&D systems: Human BDNF Quantikine ELISA Kit http://www.rndsystems.com/
Products/dbd00/; date accessed: 18.12.2014.
44. Edwards N, Gardiner M, Ritchie DM, Baldwin K, Sands L. Effect of exercise on
negative affect in residents in special care units with moderate to severe
Dementia. Alzheimer Dis Assoc Disord. 2008;22:362–8.
45. Witting W, Kwa IH, Eikelenboom P, Mirmiran M, Swaab DF. Alterations in
the circadian rest-activity rhythm in aging and Alzheimer’s disease.
Biol Psychiatry. 1990;27:563–72.
46. Kirste T, Hoffmeyer A, Koldrack P, Bauer A, Schubert S, Schröder S, et al.
Detecting the effect of Alzheimer’s disease on everyday motion behavior.
J Alzheimers Dis. 2013;38:121–32.
47. Mulsant BH. Challenges of the treatment of neuropsychiatric symptoms
associated with dementia. Am J Geriatr Psychiatr. 2014;22:317–20.
48. Raskind MA, Wang LY. Antipsychotic drugs for psychosis and agitation in
dementia: efficacy, safety, and a possible noradrenergic mechanism of
action. Int Psychogeriatr. 2014;26:879–83.
49. Rimmer J, Smith D. Alzheimer’s Disease. In: Durstine L, Moore G, Painter
P, Roberts S, editors. ACSM’s exercise management for persons with
chronic diseases and disabilities. 3rd ed. Champaign, IL: Human Kinetics;
2009. p. 368–74.
50. Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin. Demenz:
Leitlinie Langfassung. 2008th edition. Düsseldorf: Omikron Publ; 2008.
51. Staedt J, Stoppe G. Treatment of rest-activity disorders in dementia and spe-
cial focus on sundowning. Int J Geriatr Psychiatry. 2005;20:507–11.
52. Morgenthaler T, Alessi C, Friedman L, Owens J, Kapur V, Boehlecke B,
et al. Practice parameters for the use of actigraphy in the
assessment of sleep and sleep disorders: an update for 2007. Sleep.
2007;30:519–29.
53. Bankole A, Anderson M, Smith-Jackson T, Knight A, Oh K, Brantley J, et al.
Validation of noninvasive body sensor network technology in thedetection of agitation in dementia. Am J Alzheimers Dis Other Demen.
2012;27:346–54.
54. Borg G. Percieved exertion as an indicator of somatic stress. Scand J Rehabil
Med. 1970;2:92–8.
55. Yu F, Bil K. Correlating heart rate and perceived exertion during aerobic
exercise in Alzheimer’s disease. Nurs Health Sci. 2010;12:375–80.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
